Aligos Therapeutics, Inc.ALGSNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-8.2%
5Y CAGR+7.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-8.2%/yr
vs +69.4%/yr prior
5Y CAGR
+7.0%/yr
Recent deceleration
Acceleration
-77.6pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$20.46M-10.4%
2024$22.83M-25.4%
2023$30.62M+15.9%
2022$26.41M-7.4%
2021$28.53M+95.1%
2020$14.62M+46.1%
2019$10.01M+212.2%
2018$3.21M-